Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 3/20 | 0.55 |
| ▸ | SENP7 | Q9BQF6 | 3/20 | 0.55 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.55 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | CXCR2 | P25025 | 5/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2655805 | 0.78 | GCK (0.52) | RAB9ACXCR2KMT2AMEN1KDM4E | |
| SCHEMBL30901954 | 0.77 | KMT2A (0.53) | CASP3SENP7SENP8SENP6RAB9A | |
| SCHEMBL24542721 | 0.77 | KMT2A (0.53) | CASP3SENP7SENP8SENP6RAB9A | |
| SCHEMBL2656339 | 0.72 | SMN1; SMN2 (0.47) | RAB9ANPC1MAPTKMT2AMEN1 | |
| SCHEMBL2660257 | 0.71 | GCK (0.53) | CASP3SENP7SENP8SENP6RAB9A | |
| SCHEMBL2660231 | 0.70 | ADORA2A (0.47) | RAB9ANPC1MAPTKMT2AMEN1 | |
| SCHEMBL13763302 | 0.70 | MAPT (0.69) | CASP3SENP7RAB9ANPC1MAPT | |
| SCHEMBL3333586 | 0.70 | CYP3A4 (0.41) | MAPTALDH1A1POLB | |
| SCHEMBL2661038 | 0.69 | ADORA2A (0.56) | RAB9ANPC1MAPTKMT2AMEN1 | |
| SCHEMBL178984 | 0.68 | CASP3 (0.85) | CASP3SENP7SENP8SENP6RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2125735-B1 | 2,2,2-TRI-SUBSTITUTED ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION | ADVINUS THERAPEUTICS PRIVATE LTD (IN) | 2012-06-27 | — | — | EP | claimed |
| US-20100144772-A1 | 2,2,2-TRI-SUBSTITUTED ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2010-06-10 | — | — | US | claimed |
| EP-2125735-A2 | 2,2,2-TRI-SUBSTITUTED ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION | Advinus Therapeutics Private Limited (IN) | 2009-12-02 | — | — | EP | claimed |
| WO-2008104994-A2 | 2,2,2-TRI-SUBSTITUTED ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2008-09-04 | — | — | WO | claimed |
| US-8940900-B2 | 2,2,2-tri-substituted acetamide derivatives as glucokinase activators, their process and pharmaceutical application | ADVINUS THERAPEUTICS PRIVATE LIMITED (US) | 2015-01-27 | — | — | US | disclosed |
| EP-2125735-B1 | 2,2,2-TRI-SUBSTITUTED ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION | ADVINUS THERAPEUTICS PRIVATE LTD (IN) | 2012-06-27 | — | — | EP | disclosed |
| US-20100144772-A1 | 2,2,2-TRI-SUBSTITUTED ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2010-06-10 | — | — | US | disclosed |
| EP-2125735-A2 | 2,2,2-TRI-SUBSTITUTED ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION | Advinus Therapeutics Private Limited (IN) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008104994-A2 | 2,2,2-TRI-SUBSTITUTED ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION | ADVINUS THERAPEUTICS PRIVATE LIMITED (IN) | 2008-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144772-A1 | 2,2,2-TRI-SUBSTITUTED ACETAMIDE DERIVATIVES AS GLUCOKINASE ACTIVATORS, THEIR PROCESS AND PHARMACEUTICAL APPLICATION | GCK, GCKR, GALK1 | CASP3 1839/4885SENP7 1736/4885SENP8 1645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.